Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2026-03-24 00:00:00 ET · period of report 2026-03-20 · accession 0001193125-26-122272 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-24 | 2026-03-23 | CRSP | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $46.78 | -10.0K | 255.5K | -4% | -$468.7K |
| D | 2026-03-24 | 2026-03-20 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +19.7K | 265.5K | +8% | — |
| D | 2026-03-24 | 2026-03-20 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | — | -19.7K | 39.4K | -33% | — |
| DM | 2026-03-24 | 2026-03-20 | CRSP | Kulkarni Samarth | CEO, Dir | A - Grant | $0.00 | +196.1K | 114.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-03-23 | S | D | 10,020 | $46.78 | 255,501 | D | — | — | (F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| 2 | Common | Common Shares | 2026-03-20 | M | A | 19,687 | — | 265,521 | D | — | — | (F2) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. |
| 3 | Derivative | Restricted Stock Units | 2026-03-20 | M | D | 19,687 | — | 39,375 | D | — · — to — | 19,687 Common Shares | (F2) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F6) This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. |
| 4 | Derivative | Restricted Stock Units | 2026-03-20 | A | A | 81,875 | $0.00 | 81,875 | D | — · — to — | 81,875 Common Shares | (F5) This restricted stock unit award was granted on March 20, 2026 with respect to 81,875 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-03-20 | A | A | 114,249 | $0.00 | 114,249 | D | $46.24 · — to 2036-03-20 | 114,249 Common Shares | (F4) This option was granted on March 20, 2026 with respect to 114,249 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. |